On November 4, 2021 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs, reported multiple abstracts highlighting its Iomab-B and Actimab-A clinical programs have been accepted for presentation at the 63 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting being held in person and virtually in Atlanta, Georgia, December 11 – 14, 2021 (Press release, Actinium Pharmaceuticals, NOV 4, 2021, View Source [SID1234594502]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have made good progress this year in advancing Iomab-B and Actimab-A across our three active clinical trials including completing patient enrollment of the pivotal Phase 3 SIERRA trial for Iomab-B. Specifically, with Iomab-B we look forward to presenting the interim data update from full trial enrollment at ASH (Free ASH Whitepaper) prior to top line results in 2022. We are thrilled to have the opportunity to highlight the differentiated nature of our targeted radiotherapies in improving patient outcomes. We believe Iomab-B’s ability to enable near universal access to bone marrow transplant in patients who do not respond to targeted therapies can lead to a paradigm shift in targeted conditioning via both improved access and outcomes of this potentially curative procedure. Actimab-A has the potential of becoming a backbone therapy for patients with AML by leveraging the unique mechanism of targeted radiotherapy with other treatment modalities such as chemotherapy and targeted therapies which have different mechanisms of action. We have previously shown high rates of minimal residual disease negativity in patients receiving Actimab-A with CLAG-M and the mechanistic synergy of Actimab-A with Bcl-2 targeting Venetoclax. We look forward to show casing the latest data from these combination trials as well at ASH (Free ASH Whitepaper)," said Sandesh Seth, Actinium’s Chairman and CEO.

Iomab-B and Actimab-A ASH (Free ASH Whitepaper) presentation details are as follows:

Clinical Experience in the Randomized Phase 3 SIERRA Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Active, Relapsed/Refractory AML Patients Not Responding to Targeted Therapies

Session Name: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I
Date: Saturday, December 11, 2021
Presentation Time: 5:30 PM – 7:30 PM
Location: Georgia World Congress Center, Hall B5

Lintuzumab-Ac225 in Combination with CLAG-M Yields High MRD (-) Responses in R/R AML with Adverse Features: Interim Results of a Phase I Study

Session Name: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III
Date: Monday, December 13, 2021
Presentation Time: 6:00 PM – 8:00 PM
Location: Georgia World Congress Center, Hall B5

Early Clinical Evaluation of Potential Synergy of Targeted Radiotherapy with Lintuzumab-Ac225 and Venetoclax in Relapsed/Refractory AML

Session Name: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III
Date: Monday, December 13, 2021
Presentation Time: 6:00 PM – 8:00 PM
Location: Georgia World Congress Center, Hall B5